Overview
BioDuro has built comprehensive antibody discovery capabilities that stand apart from current market offerings. We apply a range of advanced technologies—including phage display, hybridoma, and synthetic antibody libraries—to generate antibodies for diverse sources. Our creative strategies are designed to overcome key challenges in antibody discovery, enabling us to generate antibodies against both common and hard-to-drug targets such as GPCRs, ion channels and intracellular proteins. This discovery engine is fully integrated with BioDuro 's broader development platform, including DMPK and oncology services, providing streamlined support from early discovery through clinical candidate selection for clients around the world.
Highlights
BioDuro delivers high-impact biologics services using cutting-edge technologies. We offer flexible engagement models with fast turnarounds for our clients. Our ADC drug discovery services include:
Efficient clone retrieval, resulting in higher quality antibody ‘hits ' in a shorter time
Biomarker discovery assays performed in non-human primates to provide representative results
Advanced therapeutic protein characterization techniques including Thermal/Colloidal characterization, Intact mass analysis, Peptide mapping, Glyco-protein profiling, Charge of variants, and Bind affinity
Exhaustive PK/PD services: wide range of animal species, tailored sampling, diverse analytical platforms, specialized biologics products
Flexible business models with custom service packages or collaborative projects
A biologics team with expertise covering antibody discovery, cancer immunotherapy, biophysics, pharmacology, and protein science
Core Competencies
Our antibody drug discovery services are supported by core scientific strengths and expertise. This includes biophysical analysis, functional assays, and in vivo animal models to assess therapeutic potential.
Antibody production
Antibody binding characterization (Biacore 8K, Octet RED 384)
Antibody stability characterization (Uncle)
In vitro/in vivo functional assays
Specialized Equipment
High-end instrumentation is necessary for complex antibody discovery workflows. Our biologics platform is powered by specialized equipment, which enables us to deliver precision, efficiency, and scalability for antibody discovery.
Gyrolab xPLore™ automated immunoassays
Triple Quad 6500+ system
Q Exactive™ Plus Hybrid Quadrupole-Orbitrap™ mass spectrometer
Biacore 8K surface plasmon resonance (SPR) system
UNCLE, all-in-one biologics stability screening platform
ECM 2001+ electrofusion and electroporation system
Octet® RED384 bio-layer interferometry (BLI) system
Systematic Antibody Discovery Service
Following early-stage screening, our customers gain access to comprehensive evaluation through BioDuro 's Systematic Antibody Discovery Services. We 've established an efficient workflow to evaluate hundreds to thousands of hits—providing representative data on affinity, stability and activity in a fast, high-throughput, and low-consumption way.
We have seven global campuses with Western-trained leadership and over 2000 scientists worldwide. All of our facilities are built to meet rigorous pharmaceutical quality and compliance standards.
High-throughput recombinant protein production system: We can rapidly clone and express tens to hundreds of target sequences simultaneously and generate purified target proteins at microgram to sub-milligram scale.
Low-consumption analysis of physical and chemical properties: Using just 10 microliters per sample, we assess thermal and colloidal stability across 48-well plates in a matter of hours, along with affinity measurements via SPR and/or BLI.
High-throughput bioactivity analysis: With high-content imaging and the Gyrolab xPLore system, we can detect relevant biomarkers and evaluate functional activity in a high-throughput format.
Why Choose BioDuro for Antibody Discovery Services
BioDuro serves as your biologics discovery and development partner. With our industry-leading technology and expertise, we 're able to address a wide variety of antibody candidates ranging from simple to complex. We have an extensive track record spanning more than 1,000 in vitro assays and 600 in vivo models.
Our integrated services span the entire discovery and development process for convenience, efficiency, and accuracy. This includes everything from target validation to IND-enabling studies. We offer flexible business models and will work with your team to implement effective research strategies from start to finish.
We have seven global campuses with Western-trained leadership and over 2000 scientists worldwide. All of our facilities are built to meet rigorous pharmaceutical quality and compliance standards.
Contact Us
Need a reliable partner for your antibody discovery project? BioDuro offers flexible and scalable services to help you meet your R&D goals.
Contact us to learn more and get started.
Q&A
What antibody discovery platforms does BioDuro use?
We use a range of platforms to discover high-affinity antibodies against challenging and complex targets. These include phage display, hybridoma, and single B-cell technologies.
Can BioDuro support antibody engineering and optimization?
Yes, we offer a variety of services to ensure candidates are clinically viable before proceeding with further research and development. These include affinity maturation, humanization, stability engineering, and developability assessment.
How does BioDuro handle high-throughput screening?
We use automated protein and analytics platforms to rapidly assess hundreds of antibody candidates in a short period of time. These assessments focus on binding ability, stability, and functional activity.
What types of therapeutic antibodies can BioDuro develop?
We support monoclonal antibodies, bispecific antibodies, multispecific antibodies, and ADCs. Our biologics discovery platform is modality-agnostic and scalable.
How does BioDuro integrate antibody discovery with downstream development?
BioDuro uses an integrated CRDMO model, which enables seamless transition from discovery biology to DMPK, oncology validation, and CMC development. This approach accelerates timelines to IND.
Home
